MedinCell S.A., 3 Rue des Frères Lumière, 34830 Jacou, France.
ACS Appl Mater Interfaces. 2023 Dec 6;15(48):55495-55509. doi: 10.1021/acsami.2c13141. Epub 2023 Nov 27.
This paper presents the and degradation of BEPO, a marketed forming depot technology used for the formulation of long-acting injectables. BEPO is composed of a solution of a blend of poly(ethylene glycol)--poly(lactic acid) (PEG-PLA) triblock and diblock in an organic solvent, where a therapeutic agent may be dissolved or suspended. Upon contact with an aqueous environment, the solvent diffuses and the polymers precipitate, entrapping the drug and forming a reservoir. Two representative BEPO compositions were subjected to a 3-month degradation study by immersion in phosphate-buffered saline at 37 °C and after subcutaneous injection in minipig. The material erosion rate, as a surrogate of the bioresorption, determined via the depot weight loss, changed substantially, depending on the composition and content of polymers within the test item. The swelling properties and internal morphology of depots were shown to be highly dependent on the solvent exchange rate during the precipitation step. Thermal analyses displayed an increase of the depot glass transition temperature over the degradation process, with no crystallinity observed at any stage. The chemical composition of degraded depots was determined by H NMR and gel permeation chromatography and demonstrated an enrichment in homopolymers, i.e., free PLA and (m)PEG, to the detriment of (m)PEG-PLA copolymers in both formulations. It was observed that the relative ratio of the degradants within the depot is driven by the initial polymer composition. Interestingly, and results showed very good qualitative consistency. Taken together, the outcomes from this study demonstrate that the different hydrolytic degradation behaviors of the BEPO compositions can be tuned by adjusting the polymer composition of the formulation.
本文介绍了 BEPO 的 和 降解,BEPO 是一种市售的形成储库技术,用于长效注射剂的配方。BEPO 由聚(乙二醇)-聚(乳酸)(PEG-PLA)三嵌段和二嵌段在有机溶剂中的混合物组成,其中治疗剂可以溶解或悬浮。与水环境接触时,溶剂扩散,聚合物沉淀,将药物包裹并形成储库。两种代表性的 BEPO 组合物在 37°C 的磷酸盐缓冲盐水和皮下注射到小型猪中的 3 个月降解研究中通过浸入进行 。通过储库重量损失来确定的生物再吸收替代物——材料侵蚀率,根据测试项目中聚合物的组成和含量而有很大变化。储库的溶胀性能和内部形态被证明高度依赖于沉淀步骤中的溶剂交换率。热分析显示储库玻璃化转变温度在降解过程中增加,在任何阶段都没有观察到结晶性。通过 H NMR 和凝胶渗透色谱法确定了降解储库的化学组成,并证明在两种配方中,均聚物(即游离 PLA 和(m)PEG)富集,而(m)PEG-PLA 共聚物减少。观察到储库内降解产物的相对比例由初始聚合物组成决定。有趣的是, 和 结果显示出非常好的定性一致性。综上所述,这项研究的结果表明,通过调整制剂的聚合物组成,可以调节 BEPO 组合物的不同水解降解行为。